Commerce Bank lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 16.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,701 shares of the biopharmaceutical company’s stock after purchasing an additional 2,191 shares during the quarter. Commerce Bank’s holdings in Halozyme Therapeutics were worth $639,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Canada Pension Plan Investment Board acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $52,000. Capula Management Ltd acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $208,000. Eqis Capital Management Inc. grew its stake in shares of Halozyme Therapeutics by 16.8% during the 2nd quarter. Eqis Capital Management Inc. now owns 5,631 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 808 shares during the period. Cambridge Investment Research Advisors Inc. grew its stake in Halozyme Therapeutics by 30.4% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 6,806 shares of the biopharmaceutical company’s stock valued at $277,000 after acquiring an additional 1,588 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in Halozyme Therapeutics by 7.5% in the 2nd quarter. Franklin Resources Inc. now owns 7,135 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 495 shares during the last quarter. 90.56% of the stock is currently owned by institutional investors and hedge funds.
In related news, CEO Helen Torley sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 8th. The shares were sold at an average price of $39.82, for a total value of $1,991,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Connie Matsui sold 32,000 shares of the firm’s stock in a transaction that occurred on Friday, November 5th. The shares were sold at an average price of $40.38, for a total transaction of $1,292,160.00. The disclosure for this sale can be found here. Corporate insiders own 2.60% of the company’s stock.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, November 2nd. The biopharmaceutical company reported $1.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $1.06. The business had revenue of $115.83 million for the quarter, compared to analyst estimates of $101.94 million. Halozyme Therapeutics had a net margin of 88.36% and a return on equity of 187.85%. During the same period in the prior year, the firm posted $0.25 EPS. Analysts expect that Halozyme Therapeutics, Inc. will post 1.82 earnings per share for the current fiscal year.
A number of brokerages recently commented on HALO. increased their price objective on shares of Halozyme Therapeutics from $27.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, December 2nd. TheStreet raised shares of Halozyme Therapeutics from a “c+” rating to a “b” rating in a research note on Monday, September 20th. Zacks Investment Research cut shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating and set a $30.00 price objective on the stock. in a research note on Thursday. SVB Leerink lowered their price objective on shares of Halozyme Therapeutics from $50.00 to $48.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 3rd. Finally, JMP Securities restated a “buy” rating and issued a $54.00 target price on shares of Halozyme Therapeutics in a report on Friday, December 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $51.25.
Halozyme Therapeutics Profile
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.